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AbsTrACT
background We investigated the association between 
cigarette smoking and risk of amyotrophic lateral 
sclerosis (aLs) in a pooled analysis of population-based 
case–control studies and explored the independent 
effects of intensity, duration and time-since-quitting.
Methods aLs cases and controls, matched by age, 
sex and region, were recruited in the Netherlands, Italy 
and Ireland (*euro-MOTOR project). Demographics 
and detailed lifetime smoking histories were collected 
through questionnaires. effects of smoking status, 
intensity (cigarettes/day), duration (years), pack-years 
and time-since-quitting (years) on aLs risk were 
estimated using logistic regression models, adjusting 
for age, sex, alcohol, education and centre. We further 
investigated effect modification of the linear effects of 
pack-years by intensity, duration and time-since-quitting 
using excess OR (eOR) models.
results analyses were performed on 1410 cases and 
2616 controls. pack-years were positively associated with 
aLs risk; OR=1.26 (95% cI: 1.03 to 1.54) for the highest 
quartile compared with never smokers. This association 
appeared to be predominantly driven by smoking 
duration (p
trend=0.001) rather than intensity (ptrend=0.86), 
although the trend for duration disappeared after 
adjustment for time-since-quitting. Time-since-quitting 
was inversely related to aLs (ptrend<0.0001). The eOR 
decreased with time-since-quitting smoking, until about 
10 years prior to disease onset. high intensity smoking 
with shorter duration appeared more deleterious than 
lower intensity for a longer duration.
Conclusions Our findings provide further support for 
the association between smoking and aLs. pack-years 
alone may be insufficient to capture effects of different 
smoking patterns. Time-since-quitting appeared to be 
an important factor, suggesting that smoking may be an 
early disease trigger.
INTroduCTIoN
Amyotrophic lateral sclerosis (ALS) is a fatal neuro-
degenerative disease. Patients typically die from 
respiratory failure, with a median survival of about 
30 months following appearance of the first symp-
toms.1 Although the aetiology of ALS is still unclear, 
time and environmental exposures are thought to 
act on genetic pre-disposition until a turning point, 
when neurodegeneration starts.2
The role of exogenous factors in the risk of ALS 
is largely unknown; only cigarette smoking has 
been considered a probable risk factor.3 Several 
mechanisms have been proposed as to how cigarette 
smoking could increase the risk of ALS, including 
oxidant compounds and chemicals, such as lead and 
formaldehyde, which are present in smoke.4
We previously reported an increased risk of ALS 
among current smokers in a Dutch case–control 
study.5 Most detailed analyses of smoking param-
eters and the risk of ALS thus far, however, have 
been performed in a large European cohort6 and in 
five cohorts in the United States.7
Overall, Gallo and colleagues found a nearly 
twofold increased risk of dying from ALS for those 
who were smokers at recruitment in comparison 
with never smokers.6 A clear relationship was 
observed between years spent smoking and ALS, 
with a stronger effect of smoking duration than 
intensity.6 Compared with continuing smoking, the 
number of years since smoking cessation was asso-
ciated with a decreased risk.6
Wang and colleagues reported an increased 
ALS risk of about 40% for smokers versus never 
smokers.7 A clear linear trend for pack-years was 
found, with a positive association for both smoking 
intensity and duration, but these findings did not 
persist when never smokers were excluded. Among 
ever smokers, younger age at smoking initiation 
was associated with an increased risk of ALS.7
The estimation of independent effects of smoking 
metrics on disease risk is complex because duration, 
intensity and time-since-quitting are interrelated. 
The modifying effects of intensity and duration 
can, however, be assessed in a model that is condi-
tioned on the linear effects of total exposure.8 This 
excess OR (eOR) model has recently been extended 
by including a direct assessment of time-since-quit-
ting smoking and the model has been successfully 
applied in lung cancer9 and Parkinson’s disease.10 
Excess relative risk models have primarily been used 
in radiation epidemiology, but have thus far hardly 
been applied in rare disease case–control settings.11
Further exploration of the effects of different 
aspects of tobacco consumption on the risk of ALS 
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may improve understanding of its aetiology. The aim of the 
current study was to investigate the risk of ALS associated with 
total pack-years of cigarette smoking in a pooled analysis of three 
population-based studies. The effect of smoking on ALS risk was 
further explored by investigating the independent contribution 
of duration, intensity and time-since cessation of smoking using 
eOR models.
MeThods
Population-based incident cases (18 years and above) with 
definite, probable or possible ALS, according to the revised 
*El Escorial Criteria,12 were recruited via population-based 
ALS registers in three European countries: the Netherlands 
(nationwide), Ireland (nationwide) and three regions in Italy 
(Apulia, Lombardy and Piedmont & Valle d’Aosta) as part of 
the Euro-MOTOR project between 2010 and 2015.13 Controls 
were matched to the cases by sex, age (±5 years) and geograph-
ical location. In Ireland and Italy, controls were individually 
matched, and in the Netherlands they were frequency matched. 
Controls were identified via the local general practitioners. All 
participants gave written informed consent.
Lifetime smoking histories were obtained through paper ques-
tionnaires, using the same questions across centres. Face-to-face 
interviews were held in Ireland and Italy. In the Netherlands, 
questionnaires were self-administered and the participants were 
contacted by telephone to complete or clarify data when neces-
sary. Smoking duration was the sum of years smoked, excluding 
the 3 years prior to the survey to eliminate any exposure that 
may have occurred after ALS diagnosis. Smoking intensity was 
the combined average number of cigarettes smoked per day 
during all smoking periods per subject. Subjects with an average 
intensity exceeding 60 cigarettes per day were excluded (n=7), 
due to possible unreliable report of intensity. Cigarette pack-
years were calculated by dividing the intensity by 20, multiplied 
by duration.
Unconditional logistic regression modelling was used to esti-
mate the main effects for smoking. ORs and 95% CIs were derived 
for smoking status (current, former, never smoker), smoking 
intensity (cigarettes per day), duration (in years), pack-years 
and time-since-quitting (in years). Categories were based on the 
quartiles of exposure distribution among controls. Models were 
adjusted for matching variables14 sex, age group (<50 years, 50 
to <60, 60 to <70, 70 to <80, and 80 and over) and centre 
(Ireland, Italy-Apulia, Italy-Lombardy, Italy-Piedmont & Val 
d’Aosta, the Netherlands), as well as for alcohol drinking status 
(current, former, never drinker) and educational level (Interna-
tional Standard Classification of Education 0–4; 5–815) . The 
reference group for the categorical analyses consisted of never 
smokers. For time-since-quitting, current smokers served as the 
reference. P values for linear trends were obtained by including 
the respective continuous variable, among ever smokers only. In 
addition, we adjusted for the other smoking metrics, excluded 
former smokers from the analyses, stratified analyses by site of 
onset (ie, spinal or bulbar) and excluded cases with the highly 
penetrant C9orf72 repeat expansion16 to see if results changed. 
We also tested for possible heterogeneity in the observed associ-
ations by applying an interaction term between exposure metric 
and study centre. To explore possible residual confounding from 
educational level, we performed the same analyses on a post-hoc 
matched case–control set.17 Matching was done at an individual 
level for sex, age, centre and educational level, and conditional 
logistic regression modelling was applied, adjusted for alcohol 
drinking status.
The potential modification of the association between pack-
years and ALS by smoking intensity, duration and time-since-
quitting was investigated in ever smokers using eOR modelling. 
These models allow for assessing the shape of the modification 
of the eOR per pack-year and can be (mathematically) described 
as follows:
 
 
 
 
 
 
OR(d) = 1 + βd ∗ exp(γ1g1(intensity))
OR(d) = 1 + βd ∗ exp(γ2g2(duration))
OR(d) = 1 + βd ∗ exp(γ3g3(time− since− quitting))
OR(d) = 1 + βd ∗ exp(γ1g1(intensity) + γ3g3(time− since− quitting))
OR(d) = 1 + βd ∗ exp(γ2g2(duration) + γ3g3time− since− quitting))  
where β is the eOR (defined as OR-1*) for each pack-year (d); 
g1, g2 and g3 are restricted cubic spline functions with knots at 
the 20th, 50th and 80th percentiles of the distribution of inten-
sity, duration and time-since-quitting, respectively, and the γs are 
the spline coefficients. Alternative knot locations and number 
of knots were assessed, but we observed minimal effects on the 
model fit (based on the Akaike Information Criterion; AIC) and 
model prediction. All analyses were therefore performed with 
the a priori specified knots, similar to Vlaanderen et al (2014).9 
We used PROC NLMIXED in SAS V.9.4 (SAS Institute, Cary, 
NC, USA) to fit the eOR models.18 Bootstrapping was used to 
estimate 95% CIs by calculating the 2.5th and 97.5th percentiles 
of the distribution for each parameter across 1000 bootstrap 
replications of the original data.
resulTs
The study population comprised 1410 ALS cases (91% of total 
cases in Euro-MOTOR) and 2616 controls (90% of total) 
with complete smoking histories and information on potential 
confounders (table 1). Over 60% of subjects were ever smokers, 
with a median total smoking estimate of 13.6 pack-years among 
controls and 17.3 among cases. The medians for smoking inten-
sity and duration were 12 cigarettes per day and 23 years for 
controls, and 14.2 cigarettes per day and 27 years for cases, 
respectively. The median time-since-quitting for former smokers 
was 25 years among controls and 22 among cases.
In the fully adjusted logistic regression models, smoking pack-
years showed a positive trend with ALS (ptrend=0.045) among ever 
smokers (table 2). The trend was stronger for smoking duration 
(ptrend=0.001) than for average smoking intensity (ptrend=0.86), 
when analysed separately. Mutual adjustment showed the same 
picture. The trend for smoking duration disappeared when the 
model was adjusted for time-since-quitting (ptrend=0.43) or when 
former smokers were excluded (ptrend=0.97, data not shown). A 
clear inverse relation with the risk of ALS (ptrend<0.0001) was 
observed for time-since-quitting smoking, which remained after 
additional adjustment for pack-years (ptrend=0.0007). Analyses 
on the post-hoc matched case–control set resulted in virtually 
the same findings (table 2). Similar findings were observed when 
stratified by site of onset or when excluding cases with C9orf72 
repeat expansions (online supplementary tables 1 and 2), and 
no significant heterogeneity between centres was observed (data 
not shown).
The eOR model that included spline functions for smoking 
duration and time-since-quitting provided the best fit to our 
data based on the AIC (data not shown). The highest risk per 
pack-year was observed for smoking durations of up to about 20 
years (figure 1, left panel). Smoking for a shorter duration with 
high intensity appeared to be more deleterious than smoking for 
a longer duration with lower intensity. The eOR per pack-year 
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Figure 1 eOR for amyotrophic lateral sclerosis per pack-year smoking by duration (left panel) and time-since-quitting (right panel) in the euro-MOTOR 
case–control study. Band=95% cI. eOR,excess OR.
steeply decreased with time-since-quitting smoking, until about 
10 years prior to the disease onset (figure 1, right panel). Similar 
patterns were observed when stratified by site of onset of disease 
(data not shown).
dIsCussIoN
A clear association between smoking and the risk of ALS was 
found in our pooled analysis of case-control studies from 
three European countries. Among ever smokers, we observed 
a continuous decrease in ALS risk with increasing time-since-
quitting smoking. This effect was also evident in the eOR 
models that included the effects of cigarette pack-years. A 
similar pattern has previously been reported for the associa-
tion between smoking and lung cancer.9 Furthermore, there 
was a suggestion that smoking many cigarettes per day for a 
shorter period was more deleterious than smoking fewer ciga-
rettes per day for longer.
From the standard logistic regression models, intensity 
of smoking did not seem to affect the association between 
total smoking and risk of ALS. This association seemed to be 
mainly driven by duration of smoking, which is in line with 
previous findings in a large European cohort.6 However, when 
time-since-quitting was added to the model, or when former 
smokers were excluded, the trend for duration disappeared, 
indicating that time-since-quitting was the strongest predictor 
of risk. Smoking duration and time-since-quitting are strongly 
correlated (Pearson’s R=−0.76), which complicates disen-
tangling their effects.19 The flexible eOR models are more 
suitable for this than standard logistic regression models, and 
results from our eOR models support the absence of an effect 
of smoking duration on the risk of ALS. Because time-since-
quitting was not controlled for, the previous reported effect of 
smoking duration on ALS6 may well have been biassed.
Flexible eOR models allow for exploration of effect 
modification of the association of cumulative exposure (ie, 
pack-years) and risk of ALS by intensity, duration, and time-
since-quitting smoking, while the effects of intensity and dura-
tion in a standard logistic regression is always distorted by the 
effect of cumulative exposure. As pack-years are the product 
of intensity and duration, a shorter smoking duration implies 
a higher number of cigarettes on average for the same total 
pack-years of smoking. We observed that the effect of one 
pack-year diminished with longer duration of smoking (and 
hence decreasing intensity) when time-since-quitting was also 
included, although CIs were wide. This observation suggests 
that intensity of smoking is influential on the association with 
ALS.
Previously, it has been suggested that six steps are needed 
to develop ALS, similar to cancer.20 These steps would 
include both genetic predisposition and environmental expo-
sures, where the last exposure can be considered the disease 
trigger. The latency between exposure and disease onset is yet 
unknown.2 However, the large variability in disease progres-
sion21 suggests that the pre-symptomatic phase may also be 
highly variable. The strong relationship with time-since-quit-
ting and the result from the eOR model, suggest that smoking 
affects the risk of ALS most in the decade before onset. Hence, 
exposure to cigarette smoke could be an early trigger for 
disease.
Although the link between smoking and ALS is not as strong 
as for lung cancer, our findings show similar patterns empha-
sising the importance of taking into account when subjects quit 
smoking. Depending on the histological type, the excess risk of 
lung cancer after 11.5 to 14.4 years since quitting smoking is 
half of that associated with continued smoking.22 Based on our 
results, the risk of ALS seemed halved in about 5 years since 
quitting smoking.
Major strength of our case-control design is that we had 
population-based controls and we were able to include clin-
ically confirmed ALS cases, instead of having to rely on the 
mention of motor neuron disease on death certificates. More-
over, the availability of detailed lifetime smoking histories for 
each subject enabled us to take into account smoking habits up 
to the start of the disease. The median time between diagnosis 
and survey completion was 15 months. We therefore chose 
to use 3 years before survey as a cut-off point for exposure to 
cigarette smoke, in order to eliminate recording of any expo-
sure that may have occurred after the onset of ALS. In cohort 
studies, such information is typically only available up to base-
line, which may ignore exposures and covariates many years 
prior to disease onset.
Our questionnaire allowed for reporting several periods of 
changing smoking habits and these changes were accounted for 
in the different metrics. In our models, however, we assigned 
the average number of cigarettes smoked per day, not taking 
into account when the changes in smoking intensity took 
place over time. The eOR model allowed us to disentangle 
the individual effects of both measures. When interpreting the 
results, however, one has to take into account the possibility 
that differential measurement error might affect the results. 
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Duration of smoking may be more accurately estimated than 
intensity, although we have no indication that such misclassi-
fication of exposure would have been different between cases 
and controls in our study. Smoking history was one of various 
aspects that were included in the questionnaire, and subjects 
were not aware of the specific hypotheses tested.
We did not a priori exclude ALS cases with a C9orf72 repeat 
expansion, as it has been suggested that external factors (such 
as smoking) may still play a role on top of their genetic load.2 
Limiting the analyses to cases with known wild type did not 
alter the overall picture. However, the risk of current smoking 
became somewhat more pronounced (OR 1.79, 95% CI 1.41 
to 2.27) as compared with the total group (OR 1.47, 95% CI 
1.20 to 1.79). Stratified analyses by site of onset revealed 
similar risks of smoking for both bulbar and spinal onset ALS.
Control subjects in our study population were overall 
more highly educated; 26% of controls were highly educated 
compared with 18% of ALS cases. We applied post-hoc 
matching for sex, age, centre and education to overcome this 
issue. The comparable findings indicate that the observed asso-
ciations were unlikely to be affected by residual confounding 
from educational level.
We used population-based controls to limit selection bias. 
Among cases, however, there may have been some bias due to 
disease progression, if smoking is also associated with survival. 
Particularly fast progressors may be underrepresented, as 
patients are possibly less likely to complete a questionnaire 
when experiencing fast deterioration. If smoking affects the 
disease progression, assuming the effect is unfavourable, our 
findings are most likely an underestimation of the true effect.
A lower body-mass index (BMI) has been associated with an 
increased risk of ALS.23 Within Euro-MOTOR, information 
on weight was collected at recruitment and for every 10 year 
life stage. Since the causal association between body-mass and 
ALS is still unclear and BMI is highly affected by the disease 
process, BMI at recruitment was not informative in our anal-
yses. Accurate information on weight prior to diagnosis was 
missing, so we were unable to adjust for possible confounding 
by premorbid BMI in the association between smoking and the 
risk of ALS.
In conclusion, our findings within the Euro-MOTOR 
case-control studies provide further support for the associa-
tion between smoking and ALS. We showed a clear decreased 
risk of ALS with time-since-quitting smoking among smokers. 
Our findings further confirm that total smoking (expressed 
as pack-years) may not be sufficient to capture the effect of 
complex smoking patterns on disease risk. Identification of 
time-varying predictors of risk could provide insights into 
the dynamics of smoking-induced ALS.24 Understanding these 
dynamics may inform hypotheses on the disease mechanism 
and will enhance insight into the aetiology of ALS.
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